Published in Curr Genomics on June 01, 2014
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol (Lausanne) (2015) 0.85
Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis. Oncotarget (2015) 0.79
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules. PLoS One (2016) 0.75
Intraoperative localization of the parathyroid glands with indocyanine green and Firefly(R) technology during BABA robotic thyroidectomy. Surg Endosc (2016) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Clinical practice. The thyroid nodule. N Engl J Med (2004) 4.84
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Thyroid carcinoma. Lancet (2003) 4.08
Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer (1997) 3.70
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 3.30
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab (2003) 2.44
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol (2003) 2.07
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin Endocrinol (Oxf) (2011) 1.61
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am (2007) 1.55
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev (2006) 1.41
Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene (1996) 1.39
Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab (2002) 1.38
Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med (2011) 1.37
Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg (2010) 1.30
The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene (2000) 1.23
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22
Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) (2007) 1.21
Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol (2008) 1.21
Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) (2006) 1.20
Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol (2002) 1.17
N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid (2000) 1.14
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol (2009) 1.13
Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem (2001) 1.13
Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol (2010) 1.13
BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab (2010) 1.13
BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol (2006) 1.12
Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab (2001) 1.11
Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol (2003) 1.11
Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med (1991) 1.09
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother (2008) 1.08
Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid (1995) 1.08
Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer (2005) 1.07
Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab (2011) 1.03
Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol (2010) 1.02
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol Metab (2012) 1.01
Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid (2003) 0.98
Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) (2008) 0.97
Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J Pediatr Surg (2004) 0.97
PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab (2004) 0.97
Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg (2010) 0.97
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007) 0.95
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer (2007) 0.93
New targeted therapies for thyroid cancer. Curr Genomics (2011) 0.93
New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer (2009) 0.91
Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology (2005) 0.90
Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol (2009) 0.89
N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery (1994) 0.87
RET TKI: potential role in thyroid cancers. Curr Oncol Rep (2012) 0.86
Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck (2012) 0.84
The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol (2009) 0.83
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab (2014) 0.83
Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg (1996) 0.83
Fine needle aspiration cytology of thyroid nodule: diagnostic accuracy and pitfalls. J Ayub Med Coll Abbottabad (2007) 0.83
Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J (2012) 0.83
New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol (2010) 0.83
Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears. Thyroid (2012) 0.82
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab (2012) 0.82
BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma. Endocr Pathol (2011) 0.79
Detection of BRAF mutation on fine needle aspiration biopsy specimens: diagnostic and clinical implications for papillary thyroid cancer. Acta Cytol (2010) 0.78
Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery (2006) 0.78
From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012. Ann Endocrinol (Paris) (2012) 0.77
Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis. Rheumatology (Oxford) (2015) 0.83
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Surgery (2014) 0.76
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncol Rep (2016) 0.76
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget (2016) 0.75
Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva Endocrinol (2015) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer. Curr Genomics (2014) 0.75
Exploring the Inter-observer Agreement Among the Members of the Italian Consensus for the Classification and Reporting of Thyroid Cytology. Endocr Pathol (2020) 0.75